{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:15:50Z","timestamp":1791270950456,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background and Objective:<\/jats:bold> Myasthenia gravis (MG) is an autoimmune neuromuscular disease. Nearly 10\u201330% of patients with MG are refractory to conventional therapy. Rituximab (RTX), a monoclonal antibody targeting CD20, is increasingly used in autoimmune disorders. We performed a systematic review and meta-analysis to evaluate the effectiveness and safety of RTX for refractory MG.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Studies published between January 1, 2000 and January 17, 2021 were searched in PubMed, EMBASE, Cochrane Library, and ClincalTrails.gov. Primary outcomes included proportion of patients achieving minimal manifestation status (MMS) or better and quantitative MG (QMG) score change from baseline. Secondary outcomes were glucocorticoids (GC) doses change from baseline and proportion of patients discontinuing oral immunosuppressants.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 24 studies involving 417 patients were included in the meta-analysis. An overall 64% (95% confidence interval, 49\u201377%) of patients achieved MMS or better. The estimated reduction of QMG score was 1.55 (95% confidence interval, 0.88\u20132.22). The mean reduction of GC doses was 1.46 (95% confidence interval, 1.10\u20131.82). The proportion of patients discontinuing oral immunosuppressants was 81% (95% confidence interval, 66\u201393%). Subgroup analyses showed that the proportion of patients achieving MMS or better and discontinuing oral immunosuppressants was higher in MuSK-MG group than those in AChR-MG group. Improvement was more pronounced in patients with mild to moderate MG compared to those with severe MG. Moreover, the efficacy appeared to be independent of the dose of RTX. 19.6% of patients experienced adverse events, most of which were mild to moderate. Only one patient developed progressive multifocal leukoencephalopathy.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> RTX can alleviate the symptom of weakness, decrease QMG score and reduce the doses of steroids and non-steroid immunosuppressive agents in refractory MG. It is well-tolerated with few severe adverse events. Randomized controlled trials are urgently needed to study the efficacy of RTX in treating refractory MG and to identify the characteristics of patients who might respond well to RTX.<\/jats:p>","DOI":"10.3389\/fneur.2021.736190","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:12:15Z","timestamp":1634148735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Cong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","article-title":"Frequency and clinical features of treatment-refractory myasthenia gravis","volume":"267","author":"Rath","year":"2020","journal-title":"J Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve."},{"key":"B19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis. three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jns.2017.02.009","article-title":"10-year-outcomes after rituximab for myasthenia gravis: efficacy, safety, costs of inhospital care, and impact on childbearing potential","volume":"375","author":"Stieglbauer","year":"2017","journal-title":"J Neurol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1166910","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"411","author":"Litchman","year":"2020","journal-title":"J Neurol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-Lasting rituximab-induced reduction of specific\u2014but not total\u2014IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.26790","article-title":"Low-dose rituximab every 6 months for the treatment of acetylcholine receptor\u2013positive refractory generalized myasthenia gravis","volume":"61","author":"Lu","year":"2020","journal-title":"Muscle Nerve."},{"key":"B25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mus.26876","article-title":"Rituximab in late-onset myasthenia gravis is safe and effective","volume":"62","author":"Sahai","year":"2020","journal-title":"Muscle Nerve."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1756286419871187","DOI":"10.1177\/1756286419871187","article-title":"Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis","volume":"12","author":"Choi","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s00415-019-09296-y","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study","volume":"266","author":"Singh","year":"2019","journal-title":"J Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.nmd.2019.06.002","article-title":"Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis","volume":"29","author":"Roda","year":"2019","journal-title":"Neuromuscular Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscular Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cort\u00e9s-Vicente","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscular Disorders."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pbj.2017.02.002","article-title":"Rituximab in generalized myasthenia gravis: clinical, quality of life and cost-utility analysis","volume":"2","author":"Peres","year":"2017","journal-title":"Porto Biomed J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positivemyasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve."},{"key":"B36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve."},{"key":"B38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis - experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol Scand."},{"key":"B42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients","author":"Illa","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in Myasthenia Gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight."},{"key":"B46","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis","volume":"85","author":"Li","year":"2021","journal-title":"J Clin Neurosci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ane.13291","article-title":"Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis","volume":"142","author":"Nepal","year":"2020","journal-title":"Acta Neurol Scand."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","article-title":"Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2019","journal-title":"Autoimmun Rev."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.736190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:12:18Z","timestamp":1634148738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.736190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":50,"alternative-id":["10.3389\/fneur.2021.736190"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.736190","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"article-number":"736190"}}